The global genome editing market size was USD 4,811.06 Mn in 2022 and is likely to reach USD 36,060.96 Mn by 2031, expanding at a CAGR of 22.31% during 2023–2031. Increasing number of genomics projects and rising production of genetically modified crops are anticipated to boost the market during the forecast period.
Genome editing is known as gene editing that involves group of technologies that allows researchers to change the DNA of an organism. This method allows alteration, addition, or removal of genes from specific locations of genome. It has application in cell line development in which cell lines are improved for considerable expression of therapeutic proteins with desired post translational modification. Furthermore, yeast cells were genetically modified to improve the production of biofuels. Crops and plants are genetically modified to enhance yield and harvest.
CRISPR-Cas9 is one of the advanced techniques used in genome editing. It is CRISPR-associated protein9 and short for regularly clustered regularly interspaced short palindrome repeats. Researcher believes that it is a rapid, cheap, and more efficient method compared to existing genome editing methods. Genome engineering has now become a potential transformative diagnostic tool, which is used by various government research centers for oncology studies.
The research report finds that the COVID-19 pandemic impacted the expansion of the genome editing market during the forecast period. Molecular biology tools including DETECTR, CARVER, PAC-MAN, ASO, CRISPR-Cas12/13-based SHERLOCK, ribozymes, aptamers, antisense peptide nucleic acids, and RNAi silencing therapies turn out to be more efficient than conventional treatment methods during the pandemic. Moreover, genome-wide association studies are new technique for discovering genes that are involved in human disease.
Genome Editing Market Dynamics
Major Drivers
Rising government funding is expected to drive the market in the coming years. Governments in several countries are investing in the field of genomics, which play a major role in the advancements of new technologies in genome editing. This investments and funding support the government institutes and academics to conduct various genome editing and engineering related projects. Genome editing technologies are helpful in managing rare diseases such as sickle-cell diseases and HIV.
In March 2020, the Ministry of Innovation, Science, and Industry (Science) invested USD 15 million for 11 genomic research projects in the agriculture, health, and environment sectors through Genome Canada. USD 29.7 million were invested by businesses, research partners, and regional government. These projects include the research on cervical and ovarian cancer.
Existing Restraints
High cost of genomic equipment and ethical concerns related to genetic research is projected to hamper the market expansion in the coming years. Genomic equipment has advanced functionalities and features, and thus the price of the equipment range between USD 10 to 20 million. High investments in multiple genomics instruments are not feasible for small and medium sized enterprises.
Emerging Opportunities
Increasing use of genome editing in personalized medicine is anticipated to create lucrative opportunities for market players. Medical practitioners identify medicine and treatment needs of patients with the help of personalized medicine. Personalized medicine is cost-effective and offers improved patient compliance, early detection of disease, and optimize various therapies.
Scope of the Genome Editing Market Report
The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes
|
Details
|
Report Title
|
Genome Editing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
Base Year
|
2022
|
Historic Data
|
2016–2021
|
Forecast Period
|
2023–2031
|
Segmentation
|
Technology (TALEN, ZFN, CRISPR, and Others), Application (Genetic Engineering, Drug Discovery, Gene-modified Cell Therapy, Diagnostics, Cell Line Engineering, and Others), and End-user (Biotechnology & Pharma Companies, Contract Research Organization, Academics & Government Institutes, and Others)
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
|
Key Players Covered in the Report
|
Agilent Technologies; GenScript; Horizon Discovery Limited; Lonza; Merck and Thermo Fisher Scientific; CRISPR Therapeutics; Danaher; Integrated DNA Technologies, Inc.; Eurofins Scientific; and Editas Medicine
|
Genome Editing Market Segment Insights
On the basis of technology, the genome editing market is segmented into TALEN, ZFN, CRISPR, and others. The CRISPR segment is projected to expand at a considerable CAGR during the forecast period, as it is used to generate chimeric antigen receptor T cells that are used to treat cancer. These T cells are extracted from patients and then treated to express chimeric antigen receptors before reinjecting into the body. Moreover, CRISPR/Cas9 treats thalassemia and sickle cell disease. The demand for CRISPR/Cas9 is increasing due to the enhanced efficiency of CRISPR/Cas9 in the identification and investigation of genetic disorders and drug discovery. The TALEN segment is anticipated to account for a major market share during the forecast period. TALEN is used to modify plant genomes to create cost-effective and nutritious food products.
Based on application, the market is divided into genetic engineering, drug discovery, gene-modified cell therapy, diagnostics, cell line engineering, and others. The gene-modified cell therapy segment is expected to hold a significant share of the market in the coming years, due to the increasing incidence of genetic disorders in several countries. Mutations and changes in the DNA sequence of an individual cause genetic diseases. Human genome editing methods are used on germline and somatic cells. Advanced genome editing techniques based on proteins include meganucleases, transcription activator-like effector nucleases (TALENs), and zinc-finger nucleases (ZFNs). The drug discovery segment accounts for a significant market share, owing to the rising technological advancements and high-grade equipment.
The cell line engineering segment is projected to register a considerable CAGR in the coming years, as it is used extensively in vaccine development, protein synthesis, drug development, and artificial tissue generation. Genetic mutations that cause diseases are corrected with the help of pluripotent stem cells (iPSCs) obtained through cell line engineering.
On the basis of end-user, the market is segregated into biotechnology & pharma companies, contract research organization, academics & government institutes, and others. The biotechnology & pharma companies segment is anticipated to expand at a substantial CAGR during the forecast period, due to the rising prevalence of infectious diseases and cancer. The biotech and pharma companies focused on producing genetically modified seeds and animals to maximize agricultural productivity. The academics & government institutes segment is expected to hold a significant share of the market in the coming years, owing to the increasing funding for genetic research.
In terms of region, the global genome editing market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the global market during the forecast period, owing to rising use of genetically modified crops and presence of research grants in the region. The market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period, due to the rising government initiatives and surging research and development activities on gene therapy in the region.
Segments
The global genome editing market has been segmented on the basis of
Technology
Application
- Genetic Engineering
- Drug Discovery
- Gene-modified Cell Therapy
- Diagnostics
- Cell Line Engineering
- Others
End-user
- Biotechnology & Pharma Companies
- Contract Research Organization
- Academics & Government Institutes
- Others
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the global genome editing market are Agilent Technologies; GenScript; Horizon Discovery Limited; Lonza; Merck and Thermo Fisher Scientific; CRISPR Therapeutics; Danaher; Integrated DNA Technologies, Inc.; Eurofins Scientific; and Editas Medicine.
Numerous players are based in emerging countries, due to the maximum technological advancements and ease of connectivity in modern times. Rapid advancements in developing countries offers new opportunities to market players.
- In February 2022, Integrated DNA Technologies unveiled Alt-R HDR donor blocks to serve the needs of researchers to push homology-directed repair genome editing research operations. Alt-R HDR Donor Blocks help scientists identify repairing disease-causing gene mutations and altering genomes to study the underlying genetic causes and treat genetic disorders.
- In October 2021, Merck KGaA a leading science and technology company, licensed its CRISPR-Cas9 technology, which is patented, to Cellecta for the improvement in next-generation treatments. This allowed Scientists and researchers to advance treatments for cancers, genetic blood disorders, and ophthalmological diseases.
- In May 2019, Thermo Fisher Scientific acquired Brammer Bio to upsurge its global presence in the market with the addition of the expertise of Brammer Bio in the manufacturing of vectors for genes and cell therapies.